The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

Vol. 20, No. 11
March 15, 1991
NOTICES

INCREASE IN TRAINING FUNDS FOR FY 1991 ............................................. 1
National Institute on Drug Abuse
Index: DRUG ABUSE

NOTICES OF AVAILABILITY (RFPs AND RFAs)

DETERMINANTS OF PERMANENT TOOTH LOSS IN THE U.S.A. (RFP) .............. 2
National Institute of Dental Research
Index: DENTAL RESEARCH

DEVELOPMENTAL STUDIES HYBRIDOMA BANK (RFP) .................................. 2
National Institute of Child Health and Human Development
Index: CHILD HEALTH, HUMAN DEVELOPMENT

CONSTRUCTION OF MOUSE PRODUCTION FACILITIES (RFA OD-91-02) .......... 3
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH

SUPERFUND HAZARDOUS SUBSTANCES BASIC RESEARCH PROGRAM (RFA ES-91-02) ...... 4
National Institute of Environmental Health Sciences
Index: ENVIRONMENTAL HEALTH SCIENCES

ONGOING PROGRAM ANNOUNCEMENTS

VULNERABILITY TO DRUG ABUSE (PA-91-33) ........................................... 6
National Institute on Drug Abuse
Index: DRUG ABUSE

INDIVIDUAL POSTDOCTORAL FELLOWSHIPS AND SENIOR FELLOWSHIPS IN
HEMATOLOGIC RESEARCH (PA-91-34) .................................................... 8
National Institute of Diabetes and Digestive and Kidney Diseases
Index: DIABETES, DIGESTIVE DISEASES, KIDNEY DISEASES, HEART, LUNG, BLOOD

NOTICES

INCREASE IN TRAINING FUNDS FOR FY 1991

P.T. 22, 44; K.W. 0720005, 0404009, 0785055, 0785035, 0715008

National Institute on Drug Abuse

In order to address the shortage of basic, epidemiologic, and clinical research scientists in the area of substance abuse and addiction, the research training budget for FY 1991 has been significantly increased for the National Institute on Drug Abuse (NIDA). As a result, NIDA is seeking additional applications for all of its basic, epidemiologic, and clinical research training programs. These programs include the following predoctoral and postdoctoral support mechanisms: National Research Service Awards for Institutional Grants, National Research Service Awards for Individual Fellows, National Research Service Awards for Research Training for Individual Fellows in Human Immunodeficiency Virus (HIV) Infection and Acquired Immunodeficiency Syndrome (AIDS), and National Research Service Awards for Institutional Research Training Grants in Human Immunodeficiency Virus (HIV) Infection and Acquired Immunodeficiency Syndrome (AIDS). Applications for these awards received on or prior to May 10, 1991, will receive an expedited review to allow their consideration for funding prior to October 1, 1991. The specific program announcements can be obtained from the Grants Management Branch, OPRM, NIDA, Room 8A-54, 5600 Fishers Lane, Rockville, Maryland 20857 (301) 443-6710. The application kits may be obtained from the Division of Research Grants, NIH, Westwood Building, Room 449, 5333 Westbard Avenue, Bethesda, MD 20892, (301) 496-7441. The original and five copies of the application must be sent to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD 20892

In order to assist us with the expedited review process, please send an additional courtesy copy of your application under separate cover to:

NIH GUIDE - Vol. 20, No. 11, March 15, 1991 - Page 1
NOTICES OF AVAILABILITY (RFPs AND RFAs)

DETERMINANTS OF PERMANENT TOOTH LOSS IN THE U.S.A.

RFP AVAILABLE: NIH-NIDR-2-91-6R

P.T. 34; K.W. 0715148, 0715020, 0785040, 0411005

National Institute of Dental Research

The National Institute of Dental Research has a requirement for a three-year study, conducted in two phases, to measure permanent tooth loss and the factors that influence it. The first phase shall collect data that describe the biological condition of extracted teeth; socioeconomic, attitudinal, economic, and dental care-seeking characteristics of persons having extractions; and selected characteristics of the dental providers who perform extractions. Results from phase 1 shall be representative of tooth loss occurring at dental settings among the civilian non-institutionalized populations in at least two, but not more than four, states from different regions in the U.S.A. The second phase shall analyze the personal, social, cultural, economic, and provider factors that influence the choice between extraction and alternative treatments, controlling for the biological condition of the teeth. In this phase, data shall be collected from patients whose teeth were treated with dental services that are alternatives to extraction for given biological conditions. The data from both phase 1 and phase 2 shall be used to analyze the relative importance of factors that influence the choice between extraction and alternatives.

This is an announcement for an anticipated Request for Proposals (RFP). It is expected that one award will be made. RFP No. NIH-NIDR-2-91-6R will be available approximately April 1, 1991, with a closing date tentatively set for May 17, 1991. Requests for the RFP must be submitted in writing, addressed to:

Marion L. Blevins
Contract Management Section
National Institute of Dental Research
National Institutes of Health
Westwood Building, Room 521
Bethesda, MD 20892

DEVELOPMENTAL STUDIES HYBRIDOMA BANK

RFP AVAILABLE: NICHD-CRMC-91-04

P.T. 34; K.W. 0760030, 0775000, 0760020, 0760045, 0710070, 0780000

National Institute of Child Health and Human Development

The National Institute of Child Health and Human Development (NICHD) is planning to continue and expand a Developmental Studies Hybridoma Bank (DSHB). The DSHB shall maintain a reserve of monoclonal antibodies that are used for research in developmental biology. The monoclonal antibodies included in the DSHB shall be directed towards molecules that are important in developmental processes. Expansion is desired in the banking of hybridomas that produce antibodies to molecules that have significance in the development of the human immune system, that are important oncogenic proteins, and that function as growth factors. The successful contractor shall maintain the current stock, acquire and develop new products, and sell and distribute the antibody products. The successful contractor will also indicate a capability in sales management in order to increase the revenues of the DSHB, which is partially self-supporting. The antibodies will be made available to qualified investigators to support and facilitate research that will lead to an improved understanding of the mechanisms of development.

This solicitation is a competitive renewal. The issuance of the Request for Proposals (RFP) will be on or about March 4, 1991, and proposals are due by 4:00 pm (Local Time), May 6, 1991. The Institute plans to make one award from this solicitation. Those organizations desiring a copy of the RFP must send a
written request to Miss Virginia A. DeSeau at the address listed below. All requests must cite the RFP number above and include two self-addressed mailing labels. All sources who consider themselves qualified are encouraged to submit proposals.

Staff Contact:
Virginia A. DeSeau
National Institute of Child Health and Human Development
Executive Plaza North, Room 515
6130 Executive Boulevard
Rockville, MD 20852
Telephone: (301) 496-4611

CONSTRUCTION OF MOUSE PRODUCTION FACILITIES

RFA AVAILABLE: OD-91-02
P.T. 34; K.W. 1002002, 1014002, 1014006
National Institutes of Health

Letter of Intent Receipt Date: April 15, 1991
Application Receipt Date: May 24, 1991

BACKGROUND INFORMATION

The Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations for 1991, provided $14,800,000 to the Office of the Director, NIH, for "extramural facilities construction grants if awarded competitively..."; the report language cited mouse production facilities in particular. Of this amount, $4,800,000 has been identified for funding two applications that were submitted in response to a previous solicitation and received high priority scores, but were not funded in Fiscal Year 1990.

Thus, in response to this latest Congressional action, the NIH is issuing RFA OD-91-02 to solicit construction grant applications for the construction of large-scale mouse production and mutant characterization facilities.

OBJECTIVES AND SCOPE

Support may be requested for the construction of new facilities and additions or renovations to existing facilities that will be dedicated to the breeding and production of specialized strains of mice, including inbred and mutant mice, necessary to meet the Nation’s needs in conducting biomedical research on a broad range of topics. Associated fixed equipment necessary for operation of these facilities may also be requested as part of the application.

MECHANISM OF SUPPORT

Any domestic, non-Federal public or non-profit private institution, organization, or association that conducts or supports biomedical research is eligible to apply.

NIH staff will verify application and award eligibility. Those judged to be unresponsive or ineligible will be returned to the investigator.

The award mechanism will be the construction grant award. Awards will be administered under Federal Regulation 45 CFR Part 74 - Administration of Grants, and 42 CFR Part 52 for cancer construction projects, and PL 101-190. This one-time solicitation based on the Fiscal Year 1991 appropriation will make available up to $10,000,000 for this initiative. Final amount to be determined will be based on the peer-review evaluation and the judgment of the Director, NIH. Up to 75 percent of the allowable costs of a project may be provided, not to exceed $10,000,000. The matching contributions by the institution may be in cash and in kind, fairly evaluated, including plant and equipment or services throughout the required 20-year period of usage of the facility (and including such specialized strains of mice as the Secretary, HHS, may request for purposes of biomedical research). Amounts provided by any agency of the Federal government, other than the Department of Health and Human Services, and services assisted or subsidized by any such agency, may be included in the amount of such matching funds. Prior to a grant award, the applicant must provide an assurance of required matching funds and that other funds have been secured to meet any projected costs in excess of the award.
amount. Requests of less than $500,000 will not be accepted. No indirect costs or continuation costs will be awarded.

For additional information, a copy of the complete RFA and application materials (Standard Form 424), please contact:

Mr. Kenneth Brow
Chief, Research Facilities Branch
Division of Cancer Biology, Diagnosis, and Centers
National Cancer Institute
Executive Plaza North, Room 300
Bethesda, MD 20892
Telephone: (301) 496-8534

Grants for research facilities construction programs of the National Institutes of Health are subject to Executive Order 12372. All awards will be made either under the authority of the Public Health Service Act, Title IV, Section 413(b)6(A) as amended by Public Law 99-158 (42 USC 285a-2) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74 and Public Law 101-190. This program is described in the Catalog of Federal Domestic Assistance, Number 93.392, Cancer-Construction.

SUPERFUND HAZARDOUS SUBSTANCES BASIC RESEARCH PROGRAM

RFA AVAILABLE: ES-91-02
P.T. 34; K.W. 1007003, 1007009, 1002016, 0760003, 0755020, 0710030
National Institute of Environmental Health Sciences

Letter of Intent Receipt Date: May 1, 1991
Application Receipt Date: June 13, 1991

PURPOSE

The National Institute of Environmental Health Sciences (NIEHS) announces the availability of funds for the continuation of a special Program of basic research and training grants directed towards understanding, assessing, and attenuating the adverse effects on human health resulting from exposure to hazardous substances. Grants made under this Program will be for coordinated, multicomponent, interdisciplinary programs. The objective is to establish and maintain a unique program linking biomedical research with related engineering, hydrogeologic, and ecologic components.

The Superfund Amendments and Reauthorization Act (SARA) of 1986 established a university-based program of basic research within the NIEHS. The NIEHS interprets its mandate under SARA to include funding for engineering, ecological, and hydrogeological research, and will support projects in these areas if they are to be performed in conjunction with biomedically related programs. The NIEHS hopes to encourage true collaborative efforts among researchers in these various areas.

RESEARCH OBJECTIVES AND SCOPE

The NIEHS Superfund Basic Research Program is intended to foster the growth of collaborative multidisciplinary research programs aimed at understanding health and environmental effects associated with hazardous waste sites and at developing improved technologies for cleaning up these sites. The focus of this Program is the effects on human health.

Strong biomedical research is a requisite of this Program. A minimum of three approved biomedical projects is required for funding. The Program expects that the non-biomedical research will be an integral part of the overall effort. All applications considered for funding must contain approved projects in both biomedical and non-biomedical areas. Further, the NIEHS intends to support graduate and advanced training in environmental and occupational health and safety, the engineering aspects of hazardous waste control, and geosciences in the setting of the research program.

Awards made under this announcement will be for a three-year period. The authorized funding level is $35 million per year. These dollar amounts are budget ceilings and actual amounts will be appropriated each year, according to the Federal budget process. Because the funding level of this program may vary from that authorized, actual award levels for approved and funded applications will be based on program balance and the availability of funds, in addition to the scientific merit considerations of the review process.
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDIES

For projects involving clinical research, NIH requires applicants to give special attention to the inclusion of women and minorities in study populations. If women and minorities are not included in the study populations for clinical studies, a specific justification for this exclusion must be provided. Applications without such documentation will not be accepted for review.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a PHS-led national activity for setting priority areas. This Request for Applications, Superfund Hazardous Substances Basic Research Program, is related to the priority area of environmental health. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, D.C. 20402-9325 (telephone 202-783-3238).

MECHANISM OF SUPPORT

The mechanism of support will be the P42 multiproject grant-in-aid for a period not to exceed three years, starting in FY 92. Administrative adjustments may be necessary to make the funding periods coincide with this time frame. It is anticipated that approximately 40 awards will be made.

THIS PROGRAM IS NOT INTENDED TO SUPPORT INDIVIDUAL RESEARCH PROJECT GRANTS.

METHOD OF APPLYING

Letters of Intent

Prospective applicants are asked to submit a brief letter of intent that includes a descriptive title of the research and responsible investigators, and identification of any other participating institutions. This letter must be received no later than MAY 1, 1991.

Application Procedure

Applications are to be submitted on form PHS 398 (revised 10/88). Forms are available from the Division of Research Grants, National Institutes of Health, Westwood Building, Room 240, 5333 Westbard Avenue, Bethesda, MD 20892-4500.

Applications must be RECEIVED at the NIEHS by JUNE 13, 1991.

THIS ANNOUNCEMENT DOES NOT CONTAIN COMPLETE APPLICATION INSTRUCTIONS FOR THIS RFA. PLEASE CONTACT PROGRAM STAFF AT NIEHS FOR FURTHER INFORMATION.

INQUIRIES

A copy of the complete RFA and program guidelines and inquiries should be directed to:

William A. Suk, Ph.D., M.P.H.
Program Administrator, Superfund Basic Research Program
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P. O. Box 12233
Research Triangle Park, NC 27709
Telephone: (919) 541-0797

Grants management inquiries should be directed to:

David L. Mineo
Chief, Grants Management Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P. O. Box 12233
Research Triangle Park, NC 27709
Telephone: (919) 541-1373
ONGOING PROGRAM ANNOUNCEMENTS

VULNERABILITY TO DRUG ABUSE

PA: PA-91-33

P.T. 34; K.W. 0404009, 0411005, 0755030

National Institute on Drug Abuse

Purpose: The etiology research program supports studies that focus on the origins of drug abuse answering questions about the causal patterns and factors leading to drug abuse. An understanding of the factors that predispose or protect an individual from drug abuse is essential to the successful prevention of drug abuse. "Vulnerability" refers to the fact that individuals are differentially at risk for engaging in drug use and for making the transition from drug use to drug abuse. A primary goal of the vulnerability research area is to develop the necessary information, theories, and methodologies to identify individuals at high risk for drug abuse. Vulnerability to the transition from drug use to abuse, and the origins of drug abuse and drug dependence, as opposed to casual, limited experimentation, are the targets of this program. Drug abusers are a heterogeneous group and there are multiple patterns of abuse, each possibly having multiple potential etiologies. An understanding of the etiology of drug abuse will make it possible to determine the critical causal factors and the most effective targets of intervention.

Areas of Research Interest: The following are representative areas of research interest.

- Behavioral Genetics Studies: Research in this area would focus on studies of the heritability, mechanisms, and markers of biologically based factors predisposing an individual to, or protecting an individual from, drug abuse and dependence. Family, twin, adoption, half sibling, and some epidemiological studies may be included.

- Physiological Studies (including neurology and biochemistry): Research in this area would focus on studies of the physiological, biochemical, and/or neurological correlates, mechanisms, and manifestations of inherited, congenital, or acquired predisposing biomedical factors. Biomedical conditions antecedent and/or concomitant to drug abuse, altered response to drugs, physiologically based deficits leading to impaired psychological function or psychopathology, and other related phenomena would also be appropriate targets of studies.

- Psychology/Psychopathology Studies (also including developmental psychopathology): Research in this area would focus on studies of the psychological, developmental, and psychopathological factors and behaviors involved in the predisposition, initiation, escalation, maintenance, and recidivism of drug abuse and dependence. Prodromal markers, developmental stage related transitions, mechanisms of predisposition or protection, relationships to personality characteristics and to other psychopathological conditions (including alcohol abuse), methodologies for early identification, principles of intervention and remediation, stress responses and the availability and form of alternate behaviors and coping skills, and other related phenomena would also be appropriate study foci. The identification of developmental stage related high-risk profiles would be an additional major goal.

- Family/Environment/Behavioral Studies: Research in this area would focus on studies of the exogenous factors that are facilitative or inhibitive of the initiation, escalation, and maintenance of drug abuse and dependence. Studies in this program component would include research on intergenerational and peer modeling and social influences; contributions of drug characteristics, availability, and delivery factors; impact of social and behavioral sanctions, consequences, and enforcement as influences.

Research Support Mechanisms: Support mechanisms include Research Projects (R01), Small Grants (R03), Conference Grants (R13), First Independent Research Support and Transition Awards (R29), Program Projects (P01) and Center Grants (P50).
IMPORTANT---The receipt dates appearing later in this announcement are for the research grant mechanism (R01). All other support mechanisms listed above may have their own: (1) receipt and review date schedule, (2) special review and award criteria, and/or (3) special programmatic considerations for funding priority. Please contact NIDA program and review staff for further information.

Eligibility: Applications for research grants may be made by public or private, for-profit or non-profit organizations, such as universities, colleges, hospitals or laboratories, units of State or local government, or authorized units of the Federal Government. Women and minority investigators, in particular, are encouraged to apply.

Application Process: Applicants must use the current version of the form PHS 398 (revised 10/88). The announcement number PA-91-33 and the title of this announcement: Vulnerability to Drug Abuse, must be typed in item #2 on the face page of the application form. Applications must adhere to page limitations noted in the application form. Complete instructions for applicants are included in the kit.

Application kits containing the necessary forms and instructions may be obtained from business offices of sponsored research at most universities, colleges, medical schools, and other major research facilities. If such a source is not available, the following office may be contacted for the necessary application material and announcements: Division of Research Grants, NIH, Nestwood Bldg., Room 449, 5333 Westbard Avenue, Bethesda, Maryland 20892, (301) 496-7441.

Review Process: Applications received under this announcement will be assigned to an initial review group for scientific merit review. Such groups consist primarily of non-Federal experts. Notification of review outcome will be sent to the applicant after the initial review. Applications will receive a secondary review for policy consideration by the appropriate National Advisory Council. Only applications recommended for approval by the National Advisory Council will be considered for funding. Applications submitted in response to this announcement are not subject to the intergovernmental review requirements of Executive Order 12372, as implemented through Department of Health and Human Services regulations at 45 CFR Part 100.

Application Receipt and Review Schedule:

<table>
<thead>
<tr>
<th>Receipt of Applications</th>
<th>Initial Review</th>
<th>Advisory Council</th>
<th>Earliest Award Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 1/July 1*</td>
<td>Oct./Nov.</td>
<td>Jan./Feb.</td>
<td>April</td>
</tr>
<tr>
<td>Oct. 1/Nov. 1*</td>
<td>Feb./March</td>
<td>May/June</td>
<td>July</td>
</tr>
<tr>
<td>Feb. 1/Mar. 1*</td>
<td>June/July</td>
<td>Sept./Oct</td>
<td>December</td>
</tr>
</tbody>
</table>

* New research grants, competing continuations, supplemental, and revised applications (new or renewal) are to be submitted on these dates. Program projects and center applications are due on the earlier date.

Consequences of Late Submission - Applications received after the above dates are subject to assignment to the next review cycle.

Inclusion on Women and Minorities in Clinical Research Study Populations:

Applications/proposals for ADAMHA grants and cooperative agreements are required to include both women and minorities in study populations for clinical research, unless compelling scientific or other justification for not including either women or minorities is provided. This requirement is intended to ensure that research findings will be of benefit to all persons at risk of the disease, disorder, or condition under study. For the purpose of these policies, clinical research involves human studies of etiology, treatment, diagnosis; prevention, or epidemiology of diseases, disorders or conditions, including but not limited to clinical trials; and minorities include U.S. racial/ethnic minority populations (specifically: American Indians or Alaskan Natives, Asian/Pacific Islanders, Blacks, and Hispanics).

ADAMHA recognizes that it may not be feasible or appropriate in all clinical research projects to include representation of the full array of U.S. racial/ethnic minority populations. However, applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups.

Applications should include a description of the composition of the proposed study population by gender and racial/ethnic group, and the rationale for the numbers and kinds of people selected to participate. This information should
Applications should incorporate in their study design gender and/or minority representation appropriate to the scientific objectives of the work proposed. If representation of women or minorities in sufficient numbers to permit assessment of differential effects is not feasible or is not appropriate, the reasons for this must be explained and justified. The rationale may relate to the purpose of the research, the health of the subjects, or other compelling circumstances (e.g., if in the only study population available there is a disproportionate representation in terms of age distribution, risk factors, incidence/prevalence, etc., of one gender or minority/majority group).

If the required information is not contained within the application, the application will be returned. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If gender and/or minority representation/justification are judged to be inadequate, reviewers will consider this as a deficiency in assigning the priority score to the application.

All applications/proposals for clinical research submitted to ADAMHA are required to address these policies. ADAMHA funding components will not award grants that do not comply with these policies.

Availability of Funds: Both research project grants and center grants will be awarded based on this announcement. It is anticipated that 4-5 research projects will be funded under this announcement during FY 1992, but will depend on availability of funds. Applications received in response to this announcement will compete for approximately $2.0 million in new grant money that has been made available for this purpose.

It is estimated that 1 new Vulnerability Center will be funded under this announcement during FY 1992. Initiation of new Centers after FY 1992 will depend on availability of funds. Center applications received in response to this announcement will compete for approximately $1.5 million in new grant money that has been made available for this purpose.

Further information and consultation on program requirements may be obtained from:

Meyer D. Glantz, Ph.D.
Acting Chief, Etiology Research Section
Prevention Research Branch
Division of Clinical Research
National Institute on Drug Abuse
5600 Fishers Lane, Rockwall Building
Rockville, MD 20857
Telephone: (301) 443-1514

INDIVIDUAL POSTDOCTORAL FELLOWSHIPS AND SENIOR FELLOWSHIPS IN HEMATOLOGIC RESEARCH

PA: PA-91-34
P.T. 22; K.W. 0785070, 0715032, 0765035, 1002058, 0790005, 0765030, 0710030

National Institute of Diabetes and Digestive and Kidney Diseases
National Heart, Lung, and Blood Institute

Application Receipt Dates: January 10, May 10, September 10

This Program Announcement emphasizes the continued interest of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart, Lung, and Blood Institute (NHLBI) in supporting the development of promising new investigators in fundamental areas of hematology, as well as in areas representing frontiers of the application of hematologic knowledge to clinical problems.

The NIDDK and the NHLBI currently have active programs supporting research across the broad area of hematology. Among the areas of primary interest, in which additional training needs exist, are approaches to understanding the fundamental processes underlying the normal and pathologic function of blood cells and the blood forming system; hemoglobin structure, function, and molecular genetic regulation; acquired and inherited hemolytic anemias; membranes and their role in cellular regulation; iron metabolism, storage, and transport; hematopoiesis and its regulation by growth factors, including erythropoietin; characterization of growth factor receptors and examination of
their role in hematopoietic stem cell differentiation; immunohematology and autoimmune disease; transplant biology; and basic approaches to gene therapy. Other research problems related to disorders of the blood or blood elements are of interest as well.

To accomplish the goals of the research programs of the NIDDK and the NHLBI, scientists who are well trained in one or more of a variety of disciplines are needed. Therefore, the NIDDK and the NHLBI are announcing the availability of individual postdoctoral fellowships to highly qualified scientists who are seeking training that will enable them to engage in research relevant to hematologic diseases. The NIDDK and the NHLBI also are interested in offering fellowships to scientists who wish to integrate mathematical, physical, chemical, as well as computer modeling approaches, with those of clinical, molecular, and cellular biology in hematologic research.

Applications received in response to this announcement will be assigned to an appropriate institute for funding consideration. Primary assignment will be determined by the research proposed in the application and its relationship to guidelines for referral of applications. Because of the mutual interests of the two Institutes in some of the areas listed above, it is recommended that questions about the assignment of an application be addressed to:

Walter Stolz, Ph.D.
Director, Division of Extramural Activities, NIDDK
National Institutes of Health
Bethesda, MD 20892

or

Ronald Geller, Ph.D.
Director, Division of Extramural Affairs, NHLBI
National Institutes of Health
Bethesda, MD 20892

Support for individual postdoctoral fellowships will be provided through the National Research Service Award (NRSA, F32). The stipend levels for the individual postdoctoral fellowships range from $18,600 to $32,300, depending on the number of years of relevant experience subsequent to the award of the doctoral degree. In addition, the training institution may request an institutional allowance of up to $3,000 per year for supplies, equipment, travel, tuition, fees, insurance, and other training-related expenses. Individual postdoctoral fellowships are made for a period of up to 3 years.

Also encouraged are applications for Senior Fellowships (NRSA, F33). Investigators who hold a doctorate or equivalent degree and have had at least seven subsequent years of relevant research or professional experience are eligible for this award. The award is designed to provide opportunities for experienced scientists to make major changes in the direction of their research careers, to acquire new research capabilities, to broaden their scientific background, to enlarge their command of an allied research field, or to take time from regular professional responsibilities to increase their capabilities for engaging in health-related research. The amount of the stipend is based on the salary from the applicant's home institution but will not exceed $32,300 per year.

Receipt dates for applications are January 10, May 10, and September 10 annually. The earliest dates that awards can be made are June, October, and February, respectively.

Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center of Research Resources may wish to identify the Center as a resource for conducting the proposed research. In such a case, a letter of agreement from the GCRC Program Director must be included in the application material.

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS

NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical research grants and cooperative agreements will be required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis should be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them. This policy is intended to apply to this pool and females of all ages. If women or minorities are excluded or inadequately represented in clinical
research, particularly in proposed population-based studies, a clear compelling rationale should be provided.

The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues should be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information should be included in the form PHS 398 in Section 2, A-D of the Research Plan AND summarized in Section 2, E, Human Subjects. Applicants/offerors are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans (including American Indians or Alaskan Natives), Asian/Pacific Islanders, Blacks, Hispanics).

The rationale for studies on single minority population groups should be provided.

For the purpose of this policy, clinical research includes human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials.

The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants.

For foreign awards, the policy on inclusion of women applies fully; since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign population groups to the United States' populations, including minorities.

If the required information is not contained within the application, the application will be returned.

Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and will be reflected in assigning the priority score to the application.

All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies.

Applications must be submitted on PHS form 416-1 (revised 7/88) that is available in the business or grants and contracts office at most academic and research institutions. In order to identify the application as a response to this Program Announcement, item 3 of the application face page must be the title "Availability of Individual Postdoctoral Fellowships and Senior Fellowships in Hematologic Research, PA-91-34." The original and two copies of the application must be mailed to:

Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Baltimore, MD 20892

For additional information about individual postdoctoral fellowship opportunities available through the NIDDK and the NHLBI, please contact:

Charles H. Rodgers, Ph.D.
Manpower Program Director
Division of Kidney, Urologic and Hematologic Diseases
NIDDK
National Institutes of Health
Bethesda, MD 20892
Telephone: (301) 496-7573
Fann Harding, Ph.D.
Special Assistant to the Director for Research Training
Division of Blood Diseases and Resources
NHLBI
National Institutes of Health
Bethesda, MD 20892
Telephone: (301) 496-1817

For fiscal and administrative matters, contact:

Florence D. Cohen
Lead Grants Clerk
Grants Management Branch, DEA
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 649
Bethesda, MD 20892
Telephone: (301) 496-7467

These programs are described in the Catalog of Federal Domestic Assistance No. 93.849 - Kidney, Urologic and Hematologic Diseases Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-411, as amended; 42 USC 241) and administered under PHS grant policies and federal regulations 42 CFR Part 52, and 45 CFR Part 74. This program is not subjected to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH. APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE ADDRESS FOR THE WESTWOOD BUILDING IS:

5333 Westbard Avenue
Bethesda, Maryland 20816